Lexicon Pharmaceuticals (LXRX) Enterprise Value (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has reported Enterprise Value for 17 consecutive years, with -$170.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value rose 12.41% year-over-year to -$170.7 million; the TTM figure through Mar 2026 stood at -$170.7 million (up 12.41% YoY), while the FY2025 annual figure was -$96.2 million, up 59.56% from the prior year.
• Enterprise Value retreated to -$170.7 million in Q1 2026 per LXRX's latest filing, from -$96.2 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$62.0 million in Q2 2022 and bottomed at -$355.6 million in Q1 2024.
• Historically, Enterprise Value has averaged -$179.6 million across 5 years, with a median of -$170.0 million in 2023.
• Annual changes were most pronounced in 2023 — Enterprise Value plunged 314.31% — and 2025, when it soared 59.56%.
• Lexicon Pharmaceuticals' Enterprise Value stood at -$138.4 million in 2022, then decreased by 22.89% to -$170.0 million in 2023, then sank by 39.95% to -$238.0 million in 2024, then jumped by 59.56% to -$96.2 million in 2025, then tumbled by 77.34% to -$170.7 million in 2026.
• Business Quant data shows LXRX's Enterprise Value at -$170.7 million in Q1 2026, -$96.2 million in Q4 2025, and -$116.0 million in Q3 2025.